"Atazanavir Sulfate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.
| Descriptor ID |
D000069446
|
| MeSH Number(s) |
D03.383.725.068 D12.644.456.157
|
| Concept/Terms |
Atazanavir- Atazanavir
- 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester
BMS 232632- BMS 232632
- 232632, BMS
- BMS-232632
- BMS232632
|
Below are MeSH descriptors whose meaning is more general than "Atazanavir Sulfate".
Below are MeSH descriptors whose meaning is more specific than "Atazanavir Sulfate".
This graph shows the total number of publications written about "Atazanavir Sulfate" by people in this website by year, and whether "Atazanavir Sulfate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 7 | 5 | 12 |
| 2018 | 13 | 4 | 17 |
| 2019 | 0 | 3 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Atazanavir Sulfate" by people in Profiles.
-
Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review. Medicine (Baltimore). 2021 Aug 06; 100(31):e26787.
-
Quantum simulations of SARS-CoV-2 main protease Mpro enable high-quality scoring of diverse ligands. J Comput Aided Mol Des. 2021 09; 35(9):963-971.
-
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients. J Med Virol. 2021 12; 93(12):6557-6565.
-
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? Eur Rev Med Pharmacol Sci. 2021 Mar; 25(5):2435-2448.
-
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Jan 04; 22(1):3.
-
Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report. Curr HIV Res. 2021; 19(4):377-382.
-
Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep. 2020 12 09; 10(1):21508.
-
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production. Antimicrob Agents Chemother. 2020 09 21; 64(10).